Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Journal of the American Dental Association (1939)
|
November 28, 2013
Authors' response
Seth V Senestraro, Jennifer Crowe, Alex Vo, et al.
Antiviral Research
|
March 7, 2025
Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivo
Steven S Good, Shouqi Luo, Kai Lin, et al.
Journal of the American Dental Association (1939)
|
August 31, 2013
Minimally invasive resin infiltration of arrested white-spot lesions: a randomized clinical trial
Seth V Senestraro, Jennifer J Crowe, Mansen Wang, et al.
The Lancet. Oncology
|
May 29, 2018
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
Rashmi Murthy, Virginia F Borges, Alison Conlin, et al.
Investigational New Drugs
|
June 12, 2014
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
Daniel W Bowles, Neil Senzer, Diana Hausman, et al.
Diagnostics (Basel, Switzerland)
|
August 29, 2024
Machine-Learning-Enabled Diagnostics with Improved Visualization of Disease Lesions in Chest X-ray Images
Md Fashiar Rahman, Tzu-Liang Bill Tseng, Michael Pokojovy, et al.
Journal of Clinical Pharmacology
|
September 27, 2025
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters
Xiao-Jian Zhou, Alex Vo, Gaetano Morelli, et al.
Journal of Clinical Pharmacology
|
April 29, 2026
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug-Metabolizing Enzymes
Xiao-Jian Zhou, Alex Vo, Gaetano Morelli, et al.
JAMA Oncology
|
June 30, 2018
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial
Virginia F Borges, Cristiano Ferrario, Nathalie Aucoin, et al.
Cancer Chemotherapy and Pharmacology
|
April 18, 2022
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
Hao Sun, Kristen A Cardinal, Larry Wienkers, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Journal of the American Dental Association (1939)
|
November 28, 2013
Authors' response
Seth V Senestraro, Jennifer Crowe, Alex Vo, et al.
Antiviral Research
|
March 7, 2025
Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivo
Steven S Good, Shouqi Luo, Kai Lin, et al.
Journal of the American Dental Association (1939)
|
August 31, 2013
Minimally invasive resin infiltration of arrested white-spot lesions: a randomized clinical trial
Seth V Senestraro, Jennifer J Crowe, Mansen Wang, et al.
The Lancet. Oncology
|
May 29, 2018
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study
Rashmi Murthy, Virginia F Borges, Alison Conlin, et al.
Investigational New Drugs
|
June 12, 2014
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
Daniel W Bowles, Neil Senzer, Diana Hausman, et al.
Diagnostics (Basel, Switzerland)
|
August 29, 2024
Machine-Learning-Enabled Diagnostics with Improved Visualization of Disease Lesions in Chest X-ray Images
Md Fashiar Rahman, Tzu-Liang Bill Tseng, Michael Pokojovy, et al.
Journal of Clinical Pharmacology
|
September 27, 2025
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters
Xiao-Jian Zhou, Alex Vo, Gaetano Morelli, et al.
Journal of Clinical Pharmacology
|
April 29, 2026
In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug-Metabolizing Enzymes
Xiao-Jian Zhou, Alex Vo, Gaetano Morelli, et al.
JAMA Oncology
|
June 30, 2018
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial
Virginia F Borges, Cristiano Ferrario, Nathalie Aucoin, et al.
Cancer Chemotherapy and Pharmacology
|
April 18, 2022
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
Hao Sun, Kristen A Cardinal, Larry Wienkers, et al.
Page
of 2